IBDEI0EN ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,6741,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6741,1,3,0)
 ;;=3^Family Hx of Genetic Disease
 ;;^UTILITY(U,$J,358.3,6741,1,4,0)
 ;;=4^Z84.81
 ;;^UTILITY(U,$J,358.3,6741,2)
 ;;=^5063392
 ;;^UTILITY(U,$J,358.3,6742,0)
 ;;=Z86.010^^30^397^76
 ;;^UTILITY(U,$J,358.3,6742,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6742,1,3,0)
 ;;=3^Personal Hx of Colonic Polyps
 ;;^UTILITY(U,$J,358.3,6742,1,4,0)
 ;;=4^Z86.010
 ;;^UTILITY(U,$J,358.3,6742,2)
 ;;=^5063456
 ;;^UTILITY(U,$J,358.3,6743,0)
 ;;=Z86.14^^30^397^81
 ;;^UTILITY(U,$J,358.3,6743,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6743,1,3,0)
 ;;=3^Personal Hx of MRSA Infection
 ;;^UTILITY(U,$J,358.3,6743,1,4,0)
 ;;=4^Z86.14
 ;;^UTILITY(U,$J,358.3,6743,2)
 ;;=^5063464
 ;;^UTILITY(U,$J,358.3,6744,0)
 ;;=Z86.31^^30^397^77
 ;;^UTILITY(U,$J,358.3,6744,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6744,1,3,0)
 ;;=3^Personal Hx of Diabetic Foot Ulcer
 ;;^UTILITY(U,$J,358.3,6744,1,4,0)
 ;;=4^Z86.31
 ;;^UTILITY(U,$J,358.3,6744,2)
 ;;=^5063467
 ;;^UTILITY(U,$J,358.3,6745,0)
 ;;=Z86.711^^30^397^107
 ;;^UTILITY(U,$J,358.3,6745,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6745,1,3,0)
 ;;=3^Personal Hx of Pulmonary Embolism
 ;;^UTILITY(U,$J,358.3,6745,1,4,0)
 ;;=4^Z86.711
 ;;^UTILITY(U,$J,358.3,6745,2)
 ;;=^5063474
 ;;^UTILITY(U,$J,358.3,6746,0)
 ;;=Z86.72^^30^397^113
 ;;^UTILITY(U,$J,358.3,6746,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6746,1,3,0)
 ;;=3^Personal Hx of Thrombophlebitis
 ;;^UTILITY(U,$J,358.3,6746,1,4,0)
 ;;=4^Z86.72
 ;;^UTILITY(U,$J,358.3,6746,2)
 ;;=^5063476
 ;;^UTILITY(U,$J,358.3,6747,0)
 ;;=Z87.310^^30^397^105
 ;;^UTILITY(U,$J,358.3,6747,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6747,1,3,0)
 ;;=3^Personal Hx of Osteoporosis Fx
 ;;^UTILITY(U,$J,358.3,6747,1,4,0)
 ;;=4^Z87.310
 ;;^UTILITY(U,$J,358.3,6747,2)
 ;;=^5063485
 ;;^UTILITY(U,$J,358.3,6748,0)
 ;;=Z87.442^^30^397^116
 ;;^UTILITY(U,$J,358.3,6748,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6748,1,3,0)
 ;;=3^Personal Hx of Urinary Calculi
 ;;^UTILITY(U,$J,358.3,6748,1,4,0)
 ;;=4^Z87.442
 ;;^UTILITY(U,$J,358.3,6748,2)
 ;;=^5063497
 ;;^UTILITY(U,$J,358.3,6749,0)
 ;;=Z87.81^^30^397^114
 ;;^UTILITY(U,$J,358.3,6749,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6749,1,3,0)
 ;;=3^Personal Hx of Traumatic Fx (Healed)
 ;;^UTILITY(U,$J,358.3,6749,1,4,0)
 ;;=4^Z87.81
 ;;^UTILITY(U,$J,358.3,6749,2)
 ;;=^5063513
 ;;^UTILITY(U,$J,358.3,6750,0)
 ;;=Z87.890^^30^397^109
 ;;^UTILITY(U,$J,358.3,6750,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6750,1,3,0)
 ;;=3^Personal Hx of Sex Reassignment
 ;;^UTILITY(U,$J,358.3,6750,1,4,0)
 ;;=4^Z87.890
 ;;^UTILITY(U,$J,358.3,6750,2)
 ;;=^5063517
 ;;^UTILITY(U,$J,358.3,6751,0)
 ;;=Z87.892^^30^397^74
 ;;^UTILITY(U,$J,358.3,6751,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6751,1,3,0)
 ;;=3^Personal Hx of Anaphylaxis
 ;;^UTILITY(U,$J,358.3,6751,1,4,0)
 ;;=4^Z87.892
 ;;^UTILITY(U,$J,358.3,6751,2)
 ;;=^5063519
 ;;^UTILITY(U,$J,358.3,6752,0)
 ;;=Z87.39^^30^397^102
 ;;^UTILITY(U,$J,358.3,6752,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6752,1,3,0)
 ;;=3^Personal Hx of Musculoskeletal/Connective Tissue Disease
 ;;^UTILITY(U,$J,358.3,6752,1,4,0)
 ;;=4^Z87.39
 ;;^UTILITY(U,$J,358.3,6752,2)
 ;;=^5063488
 ;;^UTILITY(U,$J,358.3,6753,0)
 ;;=Z87.820^^30^397^111
 ;;^UTILITY(U,$J,358.3,6753,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6753,1,3,0)
 ;;=3^Personal Hx of TBI
 ;;^UTILITY(U,$J,358.3,6753,1,4,0)
 ;;=4^Z87.820
 ;;^UTILITY(U,$J,358.3,6753,2)
 ;;=^5063514
 ;;^UTILITY(U,$J,358.3,6754,0)
 ;;=Z89.511^^30^397^8
 ;;^UTILITY(U,$J,358.3,6754,1,0)
 ;;=^358.31IA^4^2
